ArticleClinical and experimental hepatology2024
Contrast-enhanced ultrasonography as a method of monitoring focal liver lesions - initial report.
Article in Clinical and experimental hepatology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Iodized oil marking guided biopsy of hepatic space-occupying lesions under the protection of hepatic artery catheterization.BMC cancer · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim of the study: Hepatocellular adenoma (HCA) and focal nodular hyperplasia (FNH) are benign liver tumors. Hepatocellular adenoma has potential for growth, metaplasia and rupture; therefore, it should be monitored long term. In the current guidelines biopsy is not recommended in the standard diagnostic protocol. Magnetic resonance imaging (MRI) is accepted as standard in diagnostics and monitoring of these lesions. The aim of the study was to compare contrast-enhanced ultrasound (CEUS) and MRI in imaging of these tumors and determine whether CEUS can be useful in monitoring benign liver tumors. Material and methods: A retrospective analysis of 47 patients with HCA (32 tumors) and FNH (27 tumors) was carried out. A comparison between MRI and CEUS in predicting malignant transformation was performed. Results: A similar tumor enhancement profile to unchanged liver parenchyma was observed in both groups. The difference in the arterial phase was on average up to 30 dB. After 20-30 s, the enhancement of HCA and FNH in relation to the liver parenchyma was similar (difference up to 4-5 dB). Homogeneity and equalization of the tumor to background enhancement was observed until the end of the examination. The discriminative feature is the presence of a non-contrasting central fibrous scar observed in both imaging methods in the FNH group. Conclusions: CEUS can be a promising method in monitoring focal liver lesions due to low cost and low risk of complications. It is essential to analyze the early arterial phase up to 30 s to demonstrate homogeneous enhancement of the tumor and potential presence of a wash-out effect during later phases of examination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.